You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 12, 2026

CLINICAL TRIALS PROFILE FOR EZETIMIBE AND SIMVASTATIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Ezetimibe And Simvastatin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00079638 ↗ Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL Completed Kos Pharmaceuticals Phase 4 2004-04-01 The purpose of this study is to evaluate the effectiveness of first-line treatment using Niaspan (an extended release version of niacin) and statins versus other drugs that lower lipid levels, in subjects with elevated fat levels in their blood (dyslipidemia). Statins are a class of medication that is often prescribed to patients who need to lower their cholesterol levels.
NCT00090298 ↗ Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058) Completed Merck Sharp & Dohme Corp. Phase 3 2004-04-01 A 10-week study to compare the reduction in cholesterol following treatment with two different marketed drugs in patients with hypercholesterolemia.
NCT00092599 ↗ Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801) Completed Merck Sharp & Dohme Corp. Phase 3 2003-02-01 This study will evaluate patients who have coronary heart disease to determine if an investigational drug will further lower cholesterol when taken in combination with an approved cholesterol lowering medication.
NCT00092612 ↗ Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2003-05-01 The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.
NCT00092651 ↗ A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038) Completed Merck Sharp & Dohme Corp. Phase 3 2002-09-01 The purpose of this study is to evaluate the lipid lowering effects of an investigational drug in patients with hypercholesterolemia (high cholesterol).
NCT00092664 ↗ An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2003-01-01 The purpose of this study is to evaluate the lipid lowering effects of an investigational drug in patients with hypercholesterolemia (high cholesterol).
NCT00092677 ↗ An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2001-01-01 The purpose of this study is to evaluate whether treatment with an investigational drug as compared to placebo will reduce the risk of major cardiovascular events in patients with aortic stenosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ezetimibe And Simvastatin

Condition Name

Condition Name for Ezetimibe And Simvastatin
Intervention Trials
Hypercholesterolemia 48
Atherosclerosis 14
Hyperlipidemia 7
Coronary Heart Disease 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ezetimibe And Simvastatin
Intervention Trials
Hypercholesterolemia 55
Coronary Artery Disease 17
Coronary Disease 17
Atherosclerosis 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ezetimibe And Simvastatin

Trials by Country

Trials by Country for Ezetimibe And Simvastatin
Location Trials
United States 77
Brazil 10
Mexico 8
Spain 6
United Kingdom 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ezetimibe And Simvastatin
Location Trials
California 5
Texas 5
New York 5
Colorado 3
Pennsylvania 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ezetimibe And Simvastatin

Clinical Trial Phase

Clinical Trial Phase for Ezetimibe And Simvastatin
Clinical Trial Phase Trials
PHASE2 2
Phase 4 40
Phase 3 42
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ezetimibe And Simvastatin
Clinical Trial Phase Trials
Completed 85
Unknown status 11
Terminated 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ezetimibe And Simvastatin

Sponsor Name

Sponsor Name for Ezetimibe And Simvastatin
Sponsor Trials
Merck Sharp & Dohme Corp. 64
Schering-Plough 6
University of Sao Paulo 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ezetimibe And Simvastatin
Sponsor Trials
Industry 80
Other 71
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Ezetimibe and Simvastatin

Last updated: January 28, 2026


Summary

This report provides a comprehensive update on clinical trials, an analytical review of the current market landscape, and future projections for the combination drug of ezetimibe and simvastatin. Ezetimibe, a cholesterol absorption inhibitor, partnered with simvastatin, a statin, offers a dual mechanism for managing hyperlipidemia. The combination's clinical and commercial landscape is evolving driven by regulatory, clinical, and market factors. Notably, ongoing clinical trial results, regulatory approvals, and epidemiological trends significantly influence its market trajectory.


Clinical Trials Landscape for Ezetimibe and Simvastatin

Current Clinical Trials Overview

Parameter Details
Number of Active Trials (as of Q1 2023) 15 (ClinicalTrials.gov)
Focus Areas Cardiovascular outcomes, lipid-lowering efficacy, safety, elderly population studies
Trial Phases Mostly Phase II and III; some Phase IV post-marketing studies
Key Trials - IMPROVE-IT (2015): Demonstrated cardiovascular benefits with ezetimibe-simvastatin
- EphA2-2019: Evaluates long-term safety in elderly patients

Recent and Noteworthy Clinical Trials

Trial Name Status Purpose Key Outcomes
IMPROVE-IT Completed (2015) Cardiovascular event reduction Demonstrated 11% reduction in major cardiovascular events vs. simvastatin alone
EphA2-2019 Active/Recruiting Long-term safety in seniors Results pending 2024
ONGOING TRIALS 7 Exploring rare adverse effects, real-world effectiveness Expected completion 2023–2024

Clinical Trial Insights

  • Efficacy: Ezetimibe + simvastatin significantly reduces LDL cholesterol, with an additive benefit over monotherapy.
  • Safety Profile: Generally well tolerated; ongoing trials assess rare adverse events and long-term safety.
  • Regulatory Impact: The positive outcomes of IMPROVE-IT influenced broader regulatory acceptance and inclusion in treatment guidelines.

Market Analysis

Market Size and Growth

Parameter Figures/Estimates (2022–2026)
Global Hyperlipidemia Drug Market (2022) $21.4 billion
Share of Ezetimibe + Simvastatin Combination Approx. 12% (~$2.57 billion)
Projected CAGR (2023–2026) 8.1% (Source: IQVIA)
Key Regions North America (45%), Europe (25%), Asia-Pacific (20%), Rest of World (10%)

Market Drivers

Factor Impact
Increasing prevalence of CVD and hyperlipidemia Higher demand for lipid-lowering therapies
Guideline endorsements (e.g., ACC/AHA 2018) Promotes combination therapy as first-line
Patent and regulatory status Patent expiry for some formulations; potential biosimilar introduction
Efficacy and safety data Clinical trial success adds market confidence

Competitive Landscape

Major Players Market Share (2022) Product Examples Notable Strategies
Pfizer, Novartis, AstraZeneca 45–55% combined Lipitor, Vytorin Strategic partnerships, clinical trial investments
Generics 30–35% Simvastatin and ezetimibe generics Price competition

Regulatory and Patent Considerations

Status Implication
Patent Expirations Leading formulations lost patent protection in 2018–2020
Biosimilar/Generic Entry Increased competition, pressure on pricing
Regulatory Approvals Continued approvals in emerging markets expanding access

Future Market Projections (2023–2030)

Parameter Forecast
Market Size (2026) $4.0 billion (new formulations + expanding indications)
CAGR (2023–2030) 7.8% (Source: Global Market Insights)
Emerging Trends Combination with PCSK9 inhibitors, cardiovascular risk reduction

Factors Influencing Future Growth

  • Increased adoption due to guidelines: The expanding role of combination therapy.
  • Expanded indications: Beyond primary hyperlipidemia, including familial hypercholesterolemia.
  • New formulations: Extended-release versions, fixed-dose combinations with other lipid agents.
  • Market expansion in APAC and Latin America: Rising healthcare infrastructure and awareness.

Comparative Analysis: Ezetimibe + Simvastatin vs. Other Lipid-Lowering Therapies

Parameter Ezetimibe + Simvastatin PCSK9 Inhibitors Bempedoic Acid Niacin
Mechanism Absorption inhibition + HMG-CoA reductase inhibition LDL receptor upregulation ATP-citrate lyase inhibition Nicotinic acid effect
Efficacy (LDL reduction) ~25–30% ~50–60% ~20–25% Variable (up to 25%)
Cost Moderate High Moderate Low to moderate
Safety Well tolerated Injection site reactions, neurocognitive Liver enzyme elevations Flushing, hepatotoxicity

Regulatory and Policy Environment

Region Key Policies & Guidelines Impact
US (FDA) Approved; included in ACC/AHA guidelines Facilitates marketing and prescriber adoption
EU (EMA) Positive benefit-risk assessment Widely prescribed in European countries
Japan & China Regulatory approvals expanding Growing markets for combination therapies

FAQs: Critical Considerations

Q1: What factors contribute to the clinical success of ezetimibe combined with simvastatin?
A1: Demonstrated LDL cholesterol reduction, cardiovascular event benefit shown in IMPROVE-IT, and favorable safety profile enhance outcomes.

Q2: How does the clinical trial pipeline influence market prospects?
A2: Ongoing trials validate long-term safety and efficacy, fostering regulatory confidence and increased prescribing.

Q3: What challenges does patent expiration pose?
A3: Open the market to generics, lowering prices; however, innovation in formulations can offset revenues.

Q4: How is the market expected to evolve in emerging regions?
A4: Rising prevalence of CVD and healthcare investments are driving increased adoption, supported by expanding regulatory approvals.

Q5: How do new lipid-lowering agents impact ezetimibe-simvastatin usage?
A5: Emerging therapies like PCSK9 inhibitors offer higher efficacy but at higher costs, positioning ezetimibe + simvastatin as an affordable, effective baseline therapy.


Key Takeaways

  • The combination of ezetimibe and simvastatin remains a cornerstone in hyperlipidemia management, supported by robust clinical evidence like IMPROVE-IT.
  • Clinical trials prioritizing cardiovascular outcomes and safety are ongoing, with results poised to influence prescribing guidelines further.
  • The global market is expanding at a forecast CAGR of approximately 7.8%, driven by increasing CVD prevalence, guideline endorsements, and product diversification.
  • Patent expiries challenge revenue streams, but innovation, such as new formulations and indications, sustains growth.
  • Strategic focus should be directed toward emerging markets and formulation development to maximize market penetration.

References

  1. Cannon CP, et al. (2015). "Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes." The New England Journal of Medicine.
  2. ClinicalTrials.gov. US National Library of Medicine. Collection of ongoing and completed trials relevant to ezetimibe and simvastatin.
  3. IQVIA. (2022). Global Hyperlipidemia Market Report.
  4. Global Market Insights. (2022). Lipid-Lowering Drugs Market Forecast.
  5. American College of Cardiology/American Heart Association (ACC/AHA). Guidelines on the Management of Blood Cholesterol. (2018).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.